Orthocell receives Chinese patent covering its Celgro™ soft tissue reconstructive medical device platform technology

Orthocell granted Chinese patent for method to manufacture Celgro™ collagen
medical device platform technology

 Patent relates to manufacture of novel bio-scaffolds to aid in the surgical repair of
soft tissue injuries to tendons, cartilage and eardrums, and the delivery of stem cells
to the surgical site
 Orthocell has previously been granted patents for this method in Singapore and New
Zealand

Perth, Australia; 15th January 2015: Regenerative medicine company Orthocell Limited has
today announced it has been granted a Chinese patent covering the manufacture of biological
materials to repair damaged soft tissue.

The patent, described as “Chinese patent # CN 102159256 B Entitled: A Collagen Scaffold for
Cell Growth and a method producing the Same (PCT/AU2008/000583)”, relates to
Orthocell’s CelgroTM product.

“This comes at a perfect time for the company as we move our products through international
registration processes,” Orthocell Managing Director Paul Anderson said.

“It further strengthens our global intellectual property position for our unique regenerative
therapies.”

Orthocell’s novel methodology for producing a bio-scaffold device overcomes or alleviates
some of the major problems associated with other currently available bio-scaffolds which can
include:

 poor surface chemistry which provides suboptimal attachment of cells;
 acidic by-products which degrade the local pH such that cell micro-environments are
disrupted;
 immune reactions due to presence of residual foreign cells from the host and;
 lack of suitable pore size and structure and lack of sufficient mechanical properties
required to withstand the harsh environments in which bio-scaffolds are regularly
used.